Sign In
Buy VIR
$8.77
+0.0300 (+0.343%)
At Close: Jun 03, 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsir
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million
10:59am, Monday, 18'th May 2026
Vir Biotechnology develops immunology-based therapies for infectious diseases, backed by collaborations and a diversified research pipeline.
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
03:47pm, Sunday, 17'th May 2026
Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.
Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity
03:38am, Saturday, 16'th May 2026
Vir Biotechnology is rated a buy, supported by a strong cash position, pivotal late-stage pipeline, and deep institutional backing. VIR's lead CHD drugs, Tobevibart and Elebsiran, target a large, unde
Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
10:30pm, Tuesday, 12'th May 2026
Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript
06:02am, Thursday, 07'th May 2026
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
04:05pm, Wednesday, 06'th May 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2026. “Vir Bio delivered
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
04:05pm, Tuesday, 05'th May 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the B
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
04:05pm, Thursday, 23'rd Apr 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 6 to provide a corporate upd
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
08:05am, Thursday, 16'th Apr 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its global collaboration and licensing agreement with Astellas announced on February 23, 2026 has closed foll
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in one of three expansion cohorts in the Phase 1 trial evaluating VIR-5500,
Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000
09:13am, Sunday, 12'th Apr 2026
72,559 shares were sold for a total transaction value of ~$664,000 on April 6, 2026. This sale represented 6.76% of De Backer's total holdings at the time of the transaction.
Backer Marianne De Sells 72,559 Shares of Vir Biotechnology (NASDAQ:VIR) Stock
04:03am, Thursday, 09'th Apr 2026
Vir Biotechnology, Inc. (NASDAQ: VIR - Get Free Report) CEO Backer Marianne De sold 72,559 shares of the firm's stock in a transaction on Monday, April 6th. The stock was sold at an average price of $
Vir Biotechnology, Inc. $VIR Shares Sold by Citigroup Inc.
03:40am, Monday, 09'th Mar 2026
Citigroup Inc. reduced its position in Vir Biotechnology, Inc. (NASDAQ: VIR) by 22.2% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exch
Vir Biotechnology to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 26'th Feb 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the management team will participate in the following investor conferences during the month of Mar
